

BLA 761419

BLA APPROVAL

Bio-Thera Solutions, Ltd.
Attention: Lan Mu, Ph.D.
Vice President of Global Regulatory Affairs
34 Vanderveer Drive
Basking Ridge, NJ 07920

Dear Dr. Mu:

Please refer to your biologics license application (BLA) received May 22, 2024, and your amendments, submitted under section 351(k) of the Public Health Service Act for Starjemza (ustekinumab-hmny) injection for subcutaneous and intravenous administration.

BLA 761419 seeks licensure of:

- Starjemza (ustekinumab-hmny) injection 45 mg/0.5 mL and 90 mg/mL prefilled syringe (PFS) for subcutaneous use as an interchangeable biosimilar to Stelara (ustekinumab) 45 mg/0.5 mL and 90 mg/mL PFS for subcutaneous use.
- Starjemza (ustekinumab-hmny) injection 45 mg/0.5 mL single-dose vial for subcutaneous use as an interchangeable biosimilar to Stelara (ustekinumab) 45 mg/0.5 mL single-dose vial for subcutaneous use.
- Starjemza (ustekinumab-hmny) injection 130 mg/26 mL single-dose vial for intravenous use as an interchangeable biosimilar to Stelara (ustekinumab) 130 mg/26 mL single-dose vial for intravenous use.

LICENSING

We have approved your BLA for Starjemza (ustekinumab-hmny) effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, Starjemza under your existing Department of Health and Human Services U.S. License No. 2218. Starjemza (ustekinumab-hmny) is indicated for treatment of:

Adult patients with:

- moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy
- active psoriatic arthritis (PsA)
- moderately to severely active Crohn's disease (CD)

- moderately to severely active Ulcerative colitis (UC)

Pediatric patients 6 years and older with:

- moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy
- active psoriatic arthritis (PsA).

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture ustekinumab-hmny drug substance at Bio-Thera Solutions, Ltd., in Guangdong Province, China (FEI:3017231337). The final formulated drug product will be manufactured, filled, labeled, and packaged at Bio-Thera Solutions, Ltd., Guangdong Province, China (FEI: 3017231337) . You may label your product with the proprietary name, Starjemza, and market it in 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45mg/0.5mL vial and 130mg/26 mL vial.

DATING PERIOD

The dating period for the Starjemza 45 mg/0.5 ml PFS presentation shall be 36 months from the date of manufacture when stored at 2-8 °C, protected from light. The dating period for the following Starjemza presentations; 90 mg/ml PFS, 45 mg/0.5 ml vial, and 130 mg/26 ml vial, shall be 18 months from the date of manufacture when stored at 2-8°C, protected from light. The date of manufacture shall be defined as the date of final sterile filtration of the formulated drug product. The shelf-life of the final assembled/co-packaged product, Starjemza PFS, shall be on the earliest expiration date of any component, the drug product or the device. The dating period for your drug substance shall be (b) (4) months from the date of manufacture when stored at (b) (4) °C.

FDA LOT RELEASE

You are not currently required to submit samples of future lots of Starjemza to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Starjemza, or in the manufacturing facilities, will require the submission of information to your BLA for our review and written approval, consistent with 21 CFR 601.12.

APPROVAL & LABELING

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling with minor editorial revisions listed below and reflected in the enclosed labeling.

HIGHLIGHTS OF PRESCRIBING INFORMATION

- Update the Initial U.S. Approval to 2025
- Update the Revised date to 05/2025
- Update U.S. License Number to 2218
- Update copyright date to 2025

MEDICATION GUIDE

- Update U.S. License No to 2218
- Update the Approved date to 05/2025

INSTRUCTIONS FOR USE

- Update U.S. License Number to 2218
- Update the Revised date to 05/2025
- Update copyright date to 2025

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As (October 2009)*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission “**Final Printed Carton and**

¹ See <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>

U.S. Food and Drug Administration

Silver Spring, MD 20993

www.fda.gov

Container Labeling for approved BLA 761419. Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B:

We remind you of your postmarketing commitments.

4849-1 Conduct an in-use compatibility study for the BAT2206 130 mg/26 ml vial presentation that includes an IV bag and infusion line with an in-line filter to reflect the product label. These data are needed to confirm that the BAT2206 130 mg/26 ml DP is compatible with the same administration conditions as those indicated in the label of US Stelara 130 mg/26 ml vial for infusion. Detailed information on the studies performed and the data from the study will be reported in an amendment to the BLA as soon as the report is available.

The timetable you submitted on April 28, 2025, states that you will conduct this study according to the following schedule:

Study Completion: 08/2025

Final Report Submission: 08/2025

4849-2 Conduct studies to optimize sample preparation step of the polysorbate 80 (PS80) detection method to minimize the variability observed in the PS80 content for the 90 mg/mL formulation samples (45 mg/0.5 mL PFS, 90mg/1mL PFS, and 45 mg/0.5 mL vial). Detailed information on the studies performed and the data obtained will be submitted in an annual report to the BLA.

The timetable you submitted on April 30, 2025, states that you will conduct this study according to the following schedule:

Study Completion: 04/2026

Final Report Submission: 07/2026

Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this BLA. In addition, under 21 CFR 601.70 you should include a status summary of each commitment in your annual progress report of postmarketing studies to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients/subjects entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “**Postmarketing Commitment Protocol**,” “**Postmarketing Commitment Final Report**,” or “**Postmarketing Commitment Correspondence**.”

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 601.12(f)(4)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements at 21 CFR 600.80.

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements at 21 CFR 600.81.

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4207
Silver Spring, MD 20903

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.

If you have any questions, contact Farangis Rafi, Regulatory Project Manager, at (301) 796-0857 or Farangis.Rafi@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Tatiana Oussova, MD, MPH
Deputy Director for Safety
Division of Dermatology and Dentistry
Office of Immunology and Dentistry
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide
 - Instructions for Use
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

FARANGIS RAFI
05/22/2025 05:00:00 PM

TATIANA OUSSOVA
05/22/2025 05:02:17 PM